

NEW THERAPEUTIC TARGETS FOR ALZHEIMER'S DISEASE (AD)

Targeting glycan-sulfotransferases to control Tau phosphorylation and Alzheimer's disease

APPLICATIONS

- Development of anti-AD drugs

DEVELOPMENT PHASE

POC *in vitro* performed in tauopathy cell models

POC *in vivo* performed in zebrafish model

PUBLICATIONS

Sepulveda-Diaz et al., 2015. Brain

INTELLECTUAL PROPERTY

International patent application

WO2013053954

CONTACT


Mail : dda@idfinnov.com

Phone : +33(0)1 80 05 65 92

Alzheimer's disease - Tau - Tauopathy - Sulfotransferase

PRESENTATION

One of the main pathological hallmarks of Alzheimer's Disease (AD) is the presence of abnormally phosphorylated Tau protein that aggregates to form neurofibrillary tangles (NFTs), which accumulate in affected neurons to finally kill cells. Currently, the abnormal phosphorylation of Tau is considered as the 'point of no return' in AD neurodegeneration. Recent findings demonstrate that the glycan-sulfotransferase HS3ST2, responsible for the synthesis of 3-O-sulphated heparan sulphates (3OHS), is overexpressed in AD patients' brain and that 3OHS are required for the pathological phosphorylation of Tau. In a zebrafish tauopathy model, the inhibition of HS3ST2 markedly reduces Tau abnormal phosphorylation and restores the wild-type phenotype. **The present offer relates to the identification of novel potential therapeutic targets for the development of new mechanism-based anti-AD drugs, able to directly and efficiently avoid the abnormal phosphorylation of Tau protein before this occurs.**



Adapted from Karen Duff & Emmanuel Planel. Nature Medicine 11, 826 - 827 (2005). In our model, the overexpression of 3-O-sulfotransférase (2 and/or 4) leads to an increase in Tau phosphorylation and to neurodegeneration and functional deficits

COMPETITIVE ADVANTAGES

- A new mechanism-based target for AD and related tauopathies